The Science-Fiction Dream Of Producing Medicine In Earth’s Orbit Is Becoming A Reality

According to SAEDNEWS, citing Faridid, NASA has for decades provided researchers with the opportunity to study the effects of microgravity on the growth of cells, crystals, and pharmaceutical compounds. This research began during the Space Shuttle era and gained momentum after the launch of the International Space Station in the 2010s. The continuous presence of astronauts on the station has allowed scientists to conduct more complex experiments for longer periods in space.

Microgravity refers to a condition in which the effect of gravity is much weaker than on Earth. Astronauts in Earth orbit effectively experience weightlessness, and materials behave differently in such an environment. These differences have now attracted the attention of the pharmaceutical industry.

Over the past years, some experiments have shown remarkable results. One of the most notable examples occurred in 2019, when researchers succeeded in producing a more uniform and crystalline form of the anticancer drug Keytruda.

Microgravity allows drug molecules to crystallize more orderly and uniformly, which can improve drug quality.

Keytruda is one of the major cancer treatment drugs used against several types of cancer. Under normal Earth conditions, drug molecules during crystal formation are influenced by gravity, temperature, and fluid flow, which can create irregular structures. However, in microgravity, molecules assemble more slowly and evenly, forming more uniform crystals.

Most space-based pharmaceutical research has so far been supported by NASA and conducted on the International Space Station, where the high costs of transporting equipment and astronaut time were covered by the agency. However, this model was slow and time-consuming, as preparing and sending experiments could take months or even years, limiting rapid commercial development of the technology.

Now private companies such as Varda Space Industries are trying to change this process. According to Ars Technica, the company sends uncrewed capsules equipped with automated bioreactors into Earth orbit to process pharmaceutical compounds in microgravity. Varda completed its first mission, W-1, in 2023 and has since carried out several additional launches.

The field of space-based drug manufacturing has also attracted major pharmaceutical companies. Varda recently began collaboration with United Therapeutics to study the effects of microgravity on drug structure and crystallization, aiming to produce more stable and effective medicines, especially for complex lung diseases.

Under this partnership, initial experiments are conducted on Earth and promising compounds are then sent to space for testing. A significant part of this work is carried out in Varda’s new laboratory in California. The ultimate goal is to improve drug properties such as stability, solubility in the body, and more effective delivery to target tissues.

Lower launch costs and advancements in reusable rockets have made it possible to expand drug production and testing in Earth orbit.

Scientists now know that in microgravity, molecules align more uniformly and form more consistent crystals, which can improve drug performance and even reduce the need for strict storage conditions.

These developments have been enabled by rising private investment, advances in reusable rockets, and reduced launch costs. Varda spacecraft are typically launched via SpaceX missions.

Varda now has around 200 employees and $330 million in funding and is increasing its number of missions. The company aims to reach seven launches per year next year. Its vision goes beyond being a simple space company; it seeks to become a space-based pharmaceutical company that returns valuable products from orbit back to Earth.